Progestins and combined oral contraceptives in the hormonal treatment of endometriosis – a review

Kornelia Rojek
{"title":"Progestins and combined oral contraceptives in the hormonal treatment of endometriosis – a review","authors":"Kornelia Rojek","doi":"10.15584/ejcem.2023.2.21","DOIUrl":null,"url":null,"abstract":"Introduction and aim. Endometriosis is a common inflammatory disease affecting 6-10% of women of reproductive age. It is defined as the growth of endometrial-like tissue outside the uterine cavity. Dysmenorrhea, pelvic pain, dyspareunia and infertility are the main symptoms of endometriosis patients. Endometriosis treatment methods can be broadly divided into surgical and pharmacological. Currently, hormonal drugs are often used for women with endometriosis to relieve bothersome symptoms. The aim of this article is to review new publications presenting the effectiveness as well as side effects of the use of progestins and combined oral contraceptives in the hormonal treatment of endometriosis. Material and methods. A review of the literature regarding progestins and combined oral contraceptives in the treatment of endometriosis was performed using the PubMed database. In the end, 67 articles were included in this review. Analysis of the literature. Progestins and combined oral contraceptives significantly reduce dysmenorrhea, dyspareunia and pelvic pain in women with endometriosis. However, there is a risk of potential side effects, which should be taken into account when choosing a therapy for each patient individually. Conclusion. Endometriosis is a chronic disease that has a significant impact on the health-related quality of life of patients. When choosing a treatment, many aspects should be considered, primarily the patient’s preferences, drug tolerance and safety. Further drug research is needed to determine the most effective treatment for endometriosis.","PeriodicalId":11828,"journal":{"name":"European Journal of Clinical and Experimental Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Clinical and Experimental Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15584/ejcem.2023.2.21","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction and aim. Endometriosis is a common inflammatory disease affecting 6-10% of women of reproductive age. It is defined as the growth of endometrial-like tissue outside the uterine cavity. Dysmenorrhea, pelvic pain, dyspareunia and infertility are the main symptoms of endometriosis patients. Endometriosis treatment methods can be broadly divided into surgical and pharmacological. Currently, hormonal drugs are often used for women with endometriosis to relieve bothersome symptoms. The aim of this article is to review new publications presenting the effectiveness as well as side effects of the use of progestins and combined oral contraceptives in the hormonal treatment of endometriosis. Material and methods. A review of the literature regarding progestins and combined oral contraceptives in the treatment of endometriosis was performed using the PubMed database. In the end, 67 articles were included in this review. Analysis of the literature. Progestins and combined oral contraceptives significantly reduce dysmenorrhea, dyspareunia and pelvic pain in women with endometriosis. However, there is a risk of potential side effects, which should be taken into account when choosing a therapy for each patient individually. Conclusion. Endometriosis is a chronic disease that has a significant impact on the health-related quality of life of patients. When choosing a treatment, many aspects should be considered, primarily the patient’s preferences, drug tolerance and safety. Further drug research is needed to determine the most effective treatment for endometriosis.
孕激素联合口服避孕药治疗子宫内膜异位症综述
介绍和目的。子宫内膜异位症是一种常见的炎症性疾病,影响6-10%的育龄妇女。它被定义为子宫腔外生长的子宫内膜样组织。痛经、盆腔疼痛、性交困难、不孕症是子宫内膜异位症患者的主要症状。子宫内膜异位症的治疗方法大致可分为手术治疗和药物治疗。目前,激素药物常用于子宫内膜异位症患者,以缓解令人烦恼的症状。本文的目的是回顾新的出版物提出的有效性和副作用的使用黄体酮和联合口服避孕药在激素治疗子宫内膜异位症。材料和方法。使用PubMed数据库对有关孕激素和联合口服避孕药治疗子宫内膜异位症的文献进行了回顾。最终纳入67篇文献。文献分析。孕激素和联合口服避孕药可显著减少子宫内膜异位症患者的痛经、性交困难和盆腔疼痛。然而,存在潜在副作用的风险,在为每个患者单独选择治疗方法时应考虑到这一点。结论。子宫内膜异位症是一种慢性疾病,对患者的健康相关生活质量有重大影响。在选择一种治疗方法时,应考虑许多方面,主要是患者的偏好、药物耐受性和安全性。需要进一步的药物研究来确定子宫内膜异位症最有效的治疗方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.20
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信